Navigation Links
CEL-SCI Corporation Releases Letter to Shareholders
Date:2/17/2010

VIENNA, Va., Feb. 17 /PRNewswire-FirstCall/ -- The following letter is being released by CEL-SCI Corporation (NYSE CVM) to its shareholders:

Dear Fellow Shareholders:

We are pleased to report to you that the past 12 months have put CEL-SCI in the best position ever. During this difficult time we were able to complete and validate the manufacturing facility for our cancer drug Multikine, a critical step before being able to manufacture Multikine for the Phase III clinical trial.  We are developing a novel investigational treatment for H1N1 hospitalized patients and were able to take this investigational treatment into a clinical trial at Johns Hopkins University in record time.  At the same time we also raised over $40 million in new capital and added a new marketing partner for Multikine in South Africa.  Unlike the existing partners, Teva Pharmaceuticals and Orient Europharma, who will be participating in the Phase III study in Israel and parts of Asia, Byron Pharma will only be focused on marketing and will not participate in the Phase III trial.   With the manufacturing facility completed and $36 million in the bank, we are now able to start our Phase III trial for Multikine in advanced primary head and neck cancer.  

The Phase III study seeks to build on the excellent data we derived from our Phase II study of Multikine.  The data were published in several leading peer-reviewed cancer journals.  What is so impressive is that the data were derived from a well-controlled, blinded pathology study which used tumor samples from patients treated with Multikine in the last Phase II head and neck cancer study,
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
2. CEL-SCI Corporation Releases Letter to Shareholders
3. CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum
4. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
5. CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
6. CEL-SCI to Present at Rodman & Renshaw 9th Annual Healthcare Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
8. CEL-SCI Corporation Announces 2007 Financial Results
9. CEL-SCI Corporation Reports First Quarter Financial Results
10. Data Suggest CEL-SCIs CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis
11. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  CVS Caremark Corporation ... conference call on Tuesday, August 5, 2014, at 8:30 ... second quarter 2014 financial results. An audio ... through the Investor Relations portion of the CVS Caremark ... visit http://info.cvscaremark.com/investors . This webcast will be archived ...
(Date:7/25/2014)... 2014  Acsis Inc., the market leader for ... has recently posted an article, "Future of ... future needs for companies, extended supply chain, and ... model no longer work today.  The article explains ... of mobile technology, machine to machine (M2M) connectivity, ...
(Date:7/25/2014)... Research and Markets has announced the addition ... report to their offering. ... An ophthalmic diagnostic device is a ... in the human visual pathway. Ophthalmic devices are used ... glaucoma, retinal disorders, conjunctivitis, and dry eyes. ...
Breaking Medicine Technology:Acsis Addresses Questions on the Modern Supply Chain 2Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2
... on Mayo Clinic Discoveries is Developing Therapies for Wounds, ... Angiogenic Properties , , ... company,s novel technology platform which employs nano-materials made of ... wound healing, diabetic foot ulcers and hair growth are ...
... Dec. 14 Eisai Corporation of North,America today ... (FDA) has,approved LUSEDRA(TM) (fospropofol disodium) Injection, an intravenous,sedative-hypnotic ... adult,patients undergoing diagnostic or therapeutic procedures. , ... the FDA required that LUSEDRA be used only ...
Cached Medicine Technology:OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications 2OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications 3FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation 2FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation 3FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation 4
(Date:7/27/2014)... 2014 Bags underneath the eyes is one ... and there are a range of new products now available ... a baggy eyes serum review that is now posted for ... explores the issues with baggy eyes and how the natural ... users. The guide also provides a detailed overview of the ...
(Date:7/27/2014)... hepatitis E virus (HEV) transmission by blood components indicates ... HEV in their plasma. The findings, published in ... components (eg, red cells, platelets, and fresh frozen plasma) ... , The study retrospectively screened 225 000 individual ... 2012 and Sept, 2013 for HEV RNA. 79 donors ...
(Date:7/27/2014)... Ticket Down is a reputable source for ... California on November 15th. This Australian boy band has recently ... songs from this amazing album at the concert. , Tickets ... The Forum will be released for sale to the general public ... TicketDown.com. This popular secondary ticket exchange can also be reached ...
(Date:7/27/2014)... According to a new market report ... Endoscopic Operative Devices, and Visualization Systems) - Global Industry ... global endoscopy devices market was valued at USD 24.9 ... a CAGR of 6.8% from 2013 to 2019, to ... 2019. , Endoscopy procedures are performed by inserting rod ...
(Date:7/27/2014)... Scientists from The University of Manchester have discovered why medication ... findings, published in Nature Medicine , show that drugs ... clock. , In the UK pneumonia, which is ... each year and is more serious for babies, young children, ... , More than 5 million people in the UK ...
Breaking Medicine News(10 mins):Health News:Baggy Eyes Serum Review Posted for Men and Women at Cherry News Website 2Health News:The Lancet: 1 in 3000 blood donors in England infected with hepatitis E 2Health News:5 Seconds of Summer Tickets at The Forum in Inglewood (Los Angeles), CA Now Available For Sale at Ticket Down 2Health News:Global Endoscopy Devices Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Global Endoscopy Devices Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Global Endoscopy Devices Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:Drugs used to treat lung disease work with the body clock 2
... Directors and Commits all ... Work to Benefit FASTeam, CHICAGO, July 7 Fetal ... Bifida, Down Syndrome and Muscular,Dystrophy combined, yet it is a ... prevention of prenatal alcohol exposure and,research examining the effects of ...
... play a major role in,keeping the bone marrow environment ... Tenn., July 7 The lack of a single,protein ... to,recycle molecules in cells causes an incurable and often ... Hospital investigators., Children with this disease, called sialidosis, ...
... chances of miscarriage for couple, study finds , , MONDAY, ... those in which the man is over age 35 have ... study shows. , To come to this conclusion, French researchers ... fertility clinic in France. , In most of the cases, ...
... San Francisco,s Largest AIDS Fundraising Event Goes GREEN with Online ... Communications, Recycling and Awareness, ... AIDS Walk San Francisco announced today key initiatives to ,Green, ... The,initiatives include the introduction of Green Walkers, composting, and,enhanced recycling., ...
... Athens Regional Medical Center and,Blue Cross and Blue ... multi-year contract, enabling Athens Regional to join the BCBSGa,HMO/POS ... PPO contract with,Athens Regional for many years., The ... throughout,Georgia will be able to gain complete access to ...
... Physicians Practice, America,s,Leading Practice Management Journal today ... to editorial director, Steven Gottshall to associate,publisher, ... promotions,are reflective of the company,s overall strategy ... into new physician focused markets and,circulation growth., ...
Cached Medicine News:Health News:K Squared Sponsors F.A.S.T. Ride 150-mile Motorcycle Tour August 17 2Health News:St. Jude Study Reveals a New Function for an Old Enzyme in Fatal Childhood Disease 2Health News:St. Jude Study Reveals a New Function for an Old Enzyme in Fatal Childhood Disease 3Health News:St. Jude Study Reveals a New Function for an Old Enzyme in Fatal Childhood Disease 4Health News:Father's Age a Factor in Infertility 2Health News:AIDS Walk San Francisco Takes Big Green Step Forward 2Health News:AIDS Walk San Francisco Takes Big Green Step Forward 3Health News:Blue Cross and Blue Shield of Georgia and Athens Regional Medical Center Announce New HMO/POS Contract 2Health News:Physicians Practice Promotes Key Executives 2
... Pupillometry in Critical Care & Emergency ... a hand-held, cordless, and simple to use ... the measurement of the pupillary light reflex ... pupillary function which are not discernable to ...
...
Inquire...
Using proven 1064 nm technology for the treatment of deeper lesions, the Lumenis One Multi-Spot Nd:YAG module provides versatility allowing targeted treatment of leg veins, vascular lesions, facial w...
Medicine Products: